413results about How to "Low incidence of adverse reactions" patented technology

The present invention discloses a slowly-released oral medicine preparation which is made up by using breviscapine as main raw material and has the functions of promoting blood circulation and removing blood stasis, removing obstruction in the channels to relieve pain for curing angiocardiopathy and cerebrovascular disease with obvious therapeutic effect and its preparation method. Said slowly-released tablet (by one tablet) contains 60-120 mg of breviscapine, 20-75 mg of diluent, 50-150 mg of filling agent and 10-50 mg of slow release material. Said invention also provides its preparation method and concrete steps.

The invention provides medicinal compositions of taxol medicaments and pharmaceutically acceptable biological carriers and preparation method thereof. The medicinal compositions of the taxol medicaments and carrier proteins are nano mixed suspensions prepared from the carrier proteins, organic phases, stabilizers, freeze drying protective agents and the taxol medicaments. The weight volume percentconcentration of the taxol medicaments is 0.075 to 1.0. The taxol medicament nano particles prepared by using high-pressure homogenization can reduce adverse reaction aroused by the taxol medicamentsand improve the safety of the clinical administration of the taxol medicaments. The preparation process of the nano mixed suspensions is simple and feasible and is suitable for large-scale preparation and industrial production.

The invention provides an ornidazole injection. The ornidazole injection has the advantages of high stability, low impurity content, pH value that is closer to the human physiological pH value, low incidence rate of infusion pain, infusion phlebitis and other adverse reactions, etc.

The invention provides a Sirolimus slow controlled release preparation and a preparation method thereof. By adopting the solubilizing methods including a solid dispersion technology or cyclodextrin inclusion technology or adding one or a plurality of surface active agents after micronizing drugs and the like, the solubility is dramatically improved and further the bioavailability is improved, therefore, a matrix type slow controlled release preparation is made by adding one or a plurality of framework materials and other accessories, or a diaphragm-controlled or osmotic pump type slow controlled release preparation is made by adopting slow controlled release materials for coating. The Sirolimus slow controlled release preparation has better solubility and dissolution rate, high bioavailability as well as slow controlled release effect, thus being capable of maintaining steady blood concentration, bringing down the concentration of peak, reducing the occurrence of adverse reaction and improving the safety of clinical medicines, in addition, the raw materials can be acquired easily, the preparation process is simple and feasible with high yield rate and low cost, and the large-scale industrial production can be realized and the economic benefit is marked.

The present invention discloses an antiblocking hernia patch and a preparation method thereof. A polypropylene net is combined with an absorptive material chitosan antiblocking piece to prepare a partial absorptive composite mesh. The invention is characterized in that the absorptive material chitosan antiblocking piece is prepared from water-soluble chitosan by a tap casting method. The chitosan phlegm is arranged between the polypropylene net and the absorptive material chitosan antiblocking piece. The preparation method comprises the steps of preparing the chitosan antiblocking piece, uniformly coating one layer of chitosan on the polypropylene woven mesh, then placing the chitosan antiblocking piece on the polypropylene woven mesh, placing the polypropylene woven mesh between the moulds after compressing, and obtaining the antiblocking hernia patch after drying by a film isolation method in the environment at a temperature of between 15 DEG C below zero and 150 DEG C and pressure of 0 to 0.6MPa. The antiblocking hernia patch of the invention has the advantages of effectively preventing the blocking after surgery, increasing the anti-inflection effect, sustaining the excellent repairing strength, reducing the recurrence rate and complication after surgery, reducing the probability of adverse effect caused by the unthorough elimination of acid, simply controlling preparation process and eliminating the adverse effect which may be caused by the chemical process.

The invention discloses a lyophilized viper antivenin and a preparation method thereof, belonging to biochemical products, more particularly relating to an antivenin and a preparation technology thereof. The mass ratio of the antivenin and viper venom is 15:1, which can specifically neutralize the viper venom injected to mouse; as determined by immunodiffusion, the immunoprecipitation line appears in case that the ratio of viper antivenin F(ab')2 in lyophilized form to viper venom is 8:1; and other detected items conform to the quality standard of antivenin in Chinese Pharmacopoeia 2010. The detection of Phenyl-Sepharose (low-sub) FF column chromatography result shows that: activity is centralized at eluting peak 1, micromolecule impurity proteins are centralized at penetration peal, eluting peak 2 and eluting peak 3. According to the technology of the invention, immune blood plasma is resulted from viper venom immune horse, IgG is prepared by salting out the immune blood plasma, and F(ab')2 active fragment is obtained after the IgG is subject to enzymolysis and purification by a hydrophobic column. The lyophilized viper antivenin has strong specificity, high potency and more than 85% of the purity of antivenin F(ab')2 in lyophilized form.

The invention belongs to the technical field of drugs, and particularly relates to low-concentration tropane drug eye drops. The low-concentration tropane drug eye drops are prepared from 0.0005-0.5%of tropane drug, 0-10% of solute which achieves inclusion and is capable of reducing irritation, 0.01-5% of solute which increases the viscosity of drug liquid, an acidifying or alkalizing agent, an osmotic regulation agent, 0.01-0.05% of bacteriostatic agent and the balance water for injection, wherein the use amount of the acidifying or alkalizing agent enables the pH to be adjusted to be 4.0-6.5, and the use amount of the osmotic regulation agent enables the osmotic pressure to be regulated to 280-330 mOsm/L. The preparation method comprises the steps of S1, the solute which achieves inclusion and is capable of reducing irritation is weighed in proportion and solved into water, the tropane drug is added, and ultrasonic mixing is conducted for 30 minutes in an ultrasonic shake cleaning machine, so that the tropane drug is included by the solute which achieves inclusion and is capable of reducing irritation; S2, ethylparaben, sodium chloride and sodium hyaluronate are weighed in proportion and solved into the water for injection at 40-75 DEG C; S3, the solutions obtained in S1 and S2 are mixed; S4, filtration, sterilization and subpackage are conducted, and the low-concentration tropane drug eye drops are obtained.

The invention relates to a freeze-dried rabies vaccine for humans and a preparation method of the vaccine, relates to the field of vaccine production preparation technologies and aims at solving the problems that effective virus antigen expression content is low, the side effect rate of a vaccinator is high and vaccine yield and quality can not meet standard requirements as only a biological reactor is adopted for producing a rabies vaccine. The freeze-dried rabies vaccine for humans is obtained by inoculating aG strain rabies virus on Vero cells and sequentially carrying out ultrafiltration and concentration, separation and purification as well as freeze drying, wherein the packing volume of the freezed-dried rabies vaccine for human use is 0.5ml/dose, and during freeze drying, the adopted vaccine freeze-drying protecting agent comprises the following ingredients: 60-90g/l of trehalos, 6-14g/l of sodium glutamate, 3-6g/l of urea, 2-3g/l of L-arginine and 10g/l of 199 culture medium, and the vaccine freeze-drying protecting agent does not contain gelatin, human serum albumin or dextran. The freeze-dried rabies vaccine for humans has the advantages that cost is low, operation is easy, pollution is hardly produced, vaccine quality and yield are greatly improved, the content of impurities in a vaccine is reduced, allergy reactions are hardly caused, and vaccine safety is greatly improved.

The invention belongs to the blood product technology field, and discloses a preparation method for leukocyte-depleted platelet rich plasma. The method comprises the following steps: firstly, anticoagulants and blood are drawn and mixed, and whole blood to be separated is obtained; secondly, first centrifugation is carried out, a centrifugate divided into three layers from bottom to top is obtained, and platelet and plasma components in the upper layer are obtained; thirdly, the obtained upper layer components are centrifuged again, and platelet deposition at the bottom and a plasma supernatant are formed; part of the plasma supernatant is drawn, the platelet deposition is subjected to resuspension by the left plasma supernatant, and leukocyte-depleted platelet rich plasma is prepared. The method achieves elimination of leukocytes and enrichment of platelets at the same time, operation is convenient, consumed time is short, the technical indexes of the prepared plasma product are better than technical indexes of present products with the same kind. Centrifugation for two times in the method can be carried out in two centrifuge tubes respectively, or be carried out in one centrifugal device. The invention provides a centrifugal device used for performing the preparation method.

The invention discloses an ambroxol hydrochloride liquid preparation and a preparation method thereof. The method comprises the steps: dissolving ambroxol hydrochloride, stabilizing agent and osmotic pressure regulator into water used for injection, and evenly mixing together to obtain solution I; then, filtering the solution I, and obtaining the ambroxol hydrochloride liquid preparation. The preparation method does not introduce active carbon, so as to avoid the danger of hurting human body since active carbon particle is introduced into the preparation; meanwhile, the active ingredients in the preparation is ensured to be stable, and the safety (namely, the chemical stability of the ambroxol hydrochloride can be effectively improved, the particle content in the preparation is reduced, and the purity of the preparation is improved) of the finished product can be guaranteed.

The invention relates to a drug interaction modeling and risk evaluation method, terminal equipment and a storage medium. The method comprises steps that S100, a drug combination list from an electronic medical record database is obtained, and a drug interaction risk evaluation model is constructed according to the drug combination status therein; S200, to-be-inquired drug names are inputted in the drug interaction risk evaluation model, if the drug interaction risk evaluation model already has the drug combination status information of the to-be-inquired drug group, the corresponding drug interaction risk evaluation information is outputted; S300, if not, the component information of drugs in the drug group is utilized to construct a drug similarity matrix, in combination with the drug similarity matrix and the drug interaction risk evaluation model, the corresponding drug interaction risk evaluation information is outputted. The method is advantaged in that the drug interaction riskevaluation information is outputted through the drug interaction risk evaluation model, and accurate and effective decision basis is provided for reasonable clinic drug combination.

The present invention relates to a sarcopeptidoglucoside powder injection and its preparation method. It is formed from polypeptide, hydroxanthine and excipient. Said invention adopts the modern biological extraction technique to prepare sarcopeptidoglucoside solution, and utilizes the modern low-temp. freeze-drying preparation technique to obtain the invented sterile freeze-dried powder injection. When it is used, it can be dissolved by injection water or infusion fluid, then can be injected. Said invention has good stability, long storage time and high safety, etc.

The invention discloses bacteria inhibiting and balancing type gynecological gel and a preparation method thereof. The bacteria inhibiting and balancing type gynecological gel comprises the following components in percentage by weight: 0.1-2.0% of cationic biopolysaccharides, 5.0-20% of a humectant, 0.1-2.0% of a thickening agent, 5-25% of a balancing flora composite extract, 0.1-2.0% of an acidity regulator, and the balance purified water. According to the bacteria inhibiting and balancing type gynecological gel and the preparation method thereof, the components with bacteria inhibiting effect are mixed to coordinately act to inhibit pernicious bacteria and promoting the growth of probiotics; the thickening agent and cationic biopolysaccharides are mixed to coordinately act to improve the product viscosity. Therefore, the product can be conveniently used; the concentration of effective components is properly increased; moreover, the humectant is used. Therefore, a protective shield is provided for the skin, and the lubrication level of the skin is improved.

The invention relates to a SARS-CoV-2 inactivated vaccine and a preparation method of the vaccine. The preparation method comprises the following steps: step (1) recovery and large-scale culture of Vero cells; step (2) inoculation of working seeds, batch of virus seeds, virus culture and one-time harvest virus liquid, namely, the virus harvest liquid; step (3) obtaining an inactivated virus concentrated solution after a first virus inactivation, concentration and a second virus inactivation; step (4) obtaining a vaccine stock solution after purifying the inactivated virus concentrated solution; and step (5) preparation of semi-finished product and sub-package after the stock solution is verified to be qualified.

The invention relates to a long-acting fulvestrant or fulvestrant derivative sustained release preparation and preparation method of the long-acting fulvestrant or fulvestrant derivative sustained release preparation. The formula of the preparation provided by the invention comprises (1) 10mg/ml to 500mg/ml fulvestrant or fulvestrant derivative served as the active compound based on the content of preparation, (2) 3% to 80% of ketone compound or dimethyl sulfoxide served as the cosolvent based on the total weight of the preparation, (3) dispersing agent using vegetable oil or synthetic grease (ester), (4) analgesic, and (5) optional antioxidant.

The invention discloses a traditional Chinese medicine leech extract product and its application and belongs to the field of traditional Chinese medicines. The invention is characterized in that the traditional Chinese medicine leech extract product is prepared by the following steps: carrying out enzymatic hydrolysis on leech by a double-enzyme continuous enzymatic hydrolysis method (leech is firstly subjected to enzymatic hydrolysis under the acidic condition by pepsin, and an enzymolysis suspension is subjected to enzymatic hydrolysis under the alkaline condition by trypsin), carrying out ultrafiltration and nanofiltration, refining by cation exchange gel and the like, and purifying so as to obtain the leech extract product. Purity of the leech extract product reaches more than 90%. Pharmaceutical adjuncts can be added into the leech extract product to prepare a freeze-dried powder injection according to a conventional method. The traditional Chinese medicine leech extract product has a good effect of invigorating blood circulation, is used for treating cardiovascular and cerebrovascular diseases, and especially has a good effect of treating ischemia apoplexy.

A combination preparation for remedying the gastroesophageal reflux disease (GERD) and the functional dyspepsia is characterized in that the prescription of the combination preparation consists of a proton pump depressor and a gastrointestinal power drug of itopride; the proton pump depressor is selected from one of a Pantoprazole, a Omeprazole, a Esomeprazole, a Lansoprazole, a Rabeprazole, a Tenatoprazole and a Leminorazole, wherein the Pantoprazole is preferential, and at the same time the neutral form of the basic salt of the proton pump depressor is also included, such as Na^plus, Mg^2plus, Ca^2plus, K^plus or Li ^plus salt and a pure optical stereoisomer of the proton pump depressor or an active metabolite of the proton pump depressor; the gastrointestinal power drug is the itopride and a ramification of the itopride or one of the medicinal salts of the itopride; in the combination preparation, the weight ratio of the Pantoprazole and the itopride is 2 to 5 to 2 to 7. The invention has important affect for remedying the gastroesophageal reflux disease and the functional dyspepsia, and the preparation method of the invention is simple and convenient; the cost is low; the invention is fit for being orally taken by the patient; the invention has good conformance performance, high curative effect, low recrudescence rate and little adverse reaction.

The invention relates to a butylphthalide- and edaravone-containing compound injection and a preparation method thereof. The injection of every 100 ml contains 25-50 mg of active ingredient butylphthalide, 12.5-50 mg of edaravone, as well as absolute ethyl alcohol, hydroxypropyl-beta-cyclodextrin, an osmotic pressure regulator, an antioxidant and the like. With the adoption of the butylphthalide- and edaravone-containing compound injection, the administration dosage is greatly lowered, the burden of liver metabolism is reduced, and the incidence rate of liver adverse reactions is lowered. According to determination, with the adoption of the butylphthalide- and edaravone-containing compound injection, the administration dosage of the edaravone can be reduced by at least 20%, besides, the compound injection has a better curative effect, and the incidence rate of the liver adverse reactions is also remarkably lowered.

A composite medicine in the form of ointment and gels for treating psoriasis contains Tazhuluoding, betamethasone dipropionate and pharmacologically receptable auxiliary. Its advantages are high curative effect and high safety.

The invention belongs to the filed of medicines, in particular relates to a tablet containing valsartan and hydrochlorothiazide. The double-layer tablet with synergy antihypertension function provided by the invention contains 80mg/12.5mg of the valsartan and hydrochlorothiazide. Compared with a compound unilayer tablet and a capsule containing 80mg/12.5mg of the valsartan / hydrochlorothiazide, the curative effect of the tablet provided by the invention is improved, and the incidence rates of adverse effects such as hacking cough, headache and dizziness are notably reduced, and p is less than 0.05.

The invention provides a folic acid pellet preparation composed of folic acid and medical supplementary materials. The folic acid pellet preparation is characterized in that the medical supplementary materials are excipients and binders; and in the pellet preparation, the content of folic acid is 0.02-20 percent by weight, the content of excipients is 75-99.98 percent by weight, and the content of binders is 1-5 percent by weight. The pellet preparation has high dissolution rate and high bioavailability, and the preparation method is simple, convenient and easy for operation.

The invention discloses a drug recommendation modeling method based on medical record data and drug interaction risk. The method specifically comprises the following steps: S100, performing heterogeneous feature extraction operation on medical record data, outpatient medical record data and TWOSIDES drug interaction data; S200, constructing a drug recommendation sequence generation model accordingto extracted multi-source heterogeneous features; and S300, inputting patient medical records into the drug recommendation sequence generation model, and calculating and outputting recommended medication information by the model. According to the drug recommendation modeling method based on medical record data and drug interaction risks in the invention, automatic learning and modeling are performed based on massive historical case data and drug interaction information, drug recommendation information is given, an accurate and effective decision basis is provided for reasonable combination ofclinical drugs, the occurrence rate of adverse drug reactions is reduced, and effective guarantee is provided for drug use safety of users.

The invention relates to a double-layer sustained release lornoxicam tablet comprising (a) a quick release layer and (b) a sustained release layer, wherein, the quick release layer comprises (a1) the lornoxicam, (a2) alkaline matter and (a3) an other optional carrier or excipient acceptable to pharmacy and the sustained release layer comprises the (b1) lornoxicam, (b2) sustained release substance and (b3) the other optional carrier or the excipient acceptable to the pharmacy. The weight proportion of (a1) and (b1) is 1:50 to 50:1. The invention also provides a preparation method of the double-layer sustained release lornoxicam tablet. The double-layer sustained release preparation of the invention has the advantages of the quick effect of the quick release preparation and the sustained effect of sustained release preparation. In addition, the double-layer sustained release preparation can maintain the effect of effective blood concentration continuously and stably after the effective blood concentration is reached rapidly.